search
Back to results

Clonidine to Prevent Delirium After Electroconvulsive Therapy. (ECaTa)

Primary Purpose

Major Depressive Disorder, Catatonia, Bipolar Disorder

Status
Recruiting
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Clonidine
Placebo
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Major Depressive Disorder focused on measuring Electroconvulsive Therapy, ECT, Clonidine, Postictal Delirium, Postseizure Delirium, Postictal Agitation, Postseizure Agitation, CAM-ICU, RASS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18 and more;
  • Scheduled for an elective series of ambulatory ECT sessions at the University Hospital Bern;
  • Informed Consent as documented by signature (Appendix Informed Consent Form).

Exclusion Criteria:

  • Contraindications to the study drug, e. g. known allergy or hypersensitivity, hypotension, bradycardia, higher grade atrioventricular block;
  • On regular Clonidine for another indication (e.g. arterial hypertension)
  • Patients undergoing emergency ECT;
  • Unable to consent (incapable of judgment, next-of-kin consent necessary or under tutelage);
  • Inability to follow the procedures of the study, e. g. due to language barrier;
  • Previous enrolment into the current study;
  • Participation in another study with investigational drug within the 30 days preceding and during the present study;
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
  • Women who are pregnant or breast feeding;
  • Intention to become pregnant during the course of the study;
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration (and 4 weeks thereafter), such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.

Sites / Locations

  • Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of BernRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention

Control

Arm Description

The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study. At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied. The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia. Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction.

The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.

Outcomes

Primary Outcome Measures

Incidence of delirium after electroconvulsive therapy over all (twelve) ECT sessions
The primary outcome is delirium after electroconvulsive therapy over all (twelve) ECT sessions. The presence of delirium will be assessed using Confusion Assessment Method - Intensive Care Unit (CAM-ICU). To be able to perform the test correctly, the patient must be awake enough. This will be assessed using the Richmond-Agitation-Sedation-Scale (RASS) first ranging from -5 (unarousable) to +4 (combative)

Secondary Outcome Measures

Incidence of mild agitation
RASS +1, needing verbal command or short restraint < 1 minute
Incidence of severe agitation
RASS > 1, needing restraint > 1 minute or rescue medication)
Use of rescue medication
medication, dose, route
Duration of seizure activity
seconds
Quality of seizure activity
ideal, sufficient, insufficient
Seizure Quality Index
Seizure Quality Index (Kranaster et al., Eur Arch Psychiatry Clin Neurosci 2018) ranging from 0 to 5. Higher index indicates better response to treatment.
Need for seizure terminating medication
medication, dose, route
Total number of electroconvulsive therapy sessions
number
Reason for terminating or continuing the electroconvulsive series
failure, response, remission, other reason
Length of post-anaesthesia care unit stay
minutes
Incidence of desaturation
Oxygen saturation by pulse oximetry < 75%, irrespective of duration
Incidence of hypotension
any measurement with mean arterial pressure < 55 mmHg
Incidence of bradycardia
heart rate < 50 bpm for more than 1 minute
Cardiovascular changes needing intervention
number and type
Use of cardiovascular medication
medication, dose, route
Adverse events potentially attributable to ECT
diagnosis
Adverse events potentially attributable to Study Drug
diagnosis

Full Information

First Posted
March 30, 2021
Last Updated
November 1, 2022
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
University of Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT04828226
Brief Title
Clonidine to Prevent Delirium After Electroconvulsive Therapy.
Acronym
ECaTa
Official Title
Clonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 27, 2021 (Actual)
Primary Completion Date
April 27, 2025 (Anticipated)
Study Completion Date
May 27, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
University of Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Electroconvulsive therapy (ECT) is a highly effective treatment for some psychiatric disorders like major depressive or bipolar disorder, but may lead to agitation and delirium after the procedure in up to 65% of patients. This can have negative side effects and be dangerous for patient and attending staff. Clonidine, a central-acting alpha2-receptor agonist, is an approved antihypertensive medication with known sedative side effects. Clonidine's newer but more expensive successor, dexmedetomidine, has recently shown its potential to reduce this kind of delirium. The investigators therefore hypothesise that pre-treatment with 2 mcg/kg clonidine prior to electroconvulsive therapy will significantly reduce the incidence of postictal delirium. This potentially makes a highly efficient treatment for patients with otherwise refractory psychiatric illness safer and more accessible.
Detailed Description
Electroconvulsive therapy (ECT) is a highly efficacious therapy for psychiatric disorders, especially major depressive disorder, bipolar disorder and catatonia resistant to psychopharmacology or drug-psychotherapy combination therapy. At therapy induction, usually a series of 10-12 ECT sessions is planned with two to three days in between sessions. Thereafter, maintenance therapy can be continued with longer session intervals thereafter to avoid relapses and to support further drug and psychotherapy treatment. Without maintenance therapy, relapses can happen in up to 80% of all patients within one year. Nowadays conducted under general anaesthesia (etomidate in the investigator's centre) and muscle relaxation (suxamethonium) to prevent adverse events, ECT can be challenging for the anaesthesiologist, as it usually leads to rapid cardiovascular changes such as sudden bradycardia due to vagal discharge, followed by sympathetic counter regulation associated with tachycardia and hypertension. For the patient, known immediate side effects are headache in about 30% and postictal confusion and delirium in up to 65%. This confusional state can lead to involuntary movements and agitation and therefore be harmful for patients and attending staff. It usually resolves within 45 minutes but nevertheless seems to be linked with adverse side effects like persistent retrograde amnesia. Identified risk factors are long seizure time and pre-existing catatonic features. Postictal delirium has been classified by Kikuchi et. al. into four categories from no delirium, mild, moderate or severe delirium. Moderate to severe delirium needing restraints or sedative medication like benzodiazepines or Propofol was present 36% of patients, which is in line with older data. The more severe forms of delirium are easily recognised in clinical practice because of the need for intervention. When including mild forms, delirium was present in 52% of all patients in the study of Kikuchi et al. In newer studies using a more sensitive tool (CAM-ICU, Confusion Assessment Method - Intensive Care Unit) to assess the presence of delirium, the rates are up to 65% at 10 minutes after ECT stimulation respectively 10 minutes after arrival in the post-anaesthesia care unit. CAM-ICU is a brief but sensitive test, which has been extensively validated in the intensive care setting. Therefore, it seems that postictal delirium is frequently underdiagnosed in clinical practice. As we know from the intensive care literature, even hypoactive forms of delirium are associated with higher complication rates and higher mortality and therefore cannot be neglected. In previous small studies, premedication with promethazine, midazolam and dexmedetomidine successfully reduced incidence of postictal delirium. Dexmedetomidine, a highly selective, relatively short acting alpha2-agonist, has been more extensively studied in the setting of ECT and has recently been able to show his potency to reduce postictal delirium by a third when given as a bolus pre-induction in a randomised controlled trial. In this prospective, randomised, placebo-controlled, triple-blind, single-centre, two-arm parallel groups superiority trial, the investigators aim to lower incidence and severity of postictal delirium and agitation using a pre-induction dose of 2 mcg/kg clonidine intravenously compared to placebo (sodium chloride). The investigators also hypothesise, that a pre-induction dose of clonidine will reduce incidence of postictal agitation, the need for sedative rescue medication and the need for short-acting antihypertensive medication. It therefore might increase patient safety and cost effectiveness without prolonging post-anaesthesia care unit stay or negatively affecting treatment efficacy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder, Catatonia, Bipolar Disorder, Delirium Postseizure
Keywords
Electroconvulsive Therapy, ECT, Clonidine, Postictal Delirium, Postseizure Delirium, Postictal Agitation, Postseizure Agitation, CAM-ICU, RASS

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
This is a prospective, randomised, placebo-controlled, triple blind, single-centre, two-arm parallel groups superiority trial assessing incidence and severity of postictal delirium.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
After randomisation in RedCap, a study nurse otherwise not involved in the trial will store group allocation in an envelope (labelled with the patients study identifier, name and date of birth) in a closed cupboard accessible to the post-anaesthesia care team member preparing the study drug, but not the treating or assessing team. After a patient's trial completion, the envelope and its content will be destroyed. Therefore, the treating team, the patient as well as the data collecting personnel is blinded to group allocation. The bottles containing study drug or placebo are identical and are identically labelled with "Study Drug" and the patients name by the independent post-anaesthesia care member preparing the study drug before ECT sessions start. Data analysts will be blinded as well because allocation to verum or placebo is only known to the study nurse randomising patients and preparing the envelopes needed for drug preparation.
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study. At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied. The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia. Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
Intervention Type
Drug
Intervention Name(s)
Clonidine
Other Intervention Name(s)
Verum
Intervention Description
Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
Primary Outcome Measure Information:
Title
Incidence of delirium after electroconvulsive therapy over all (twelve) ECT sessions
Description
The primary outcome is delirium after electroconvulsive therapy over all (twelve) ECT sessions. The presence of delirium will be assessed using Confusion Assessment Method - Intensive Care Unit (CAM-ICU). To be able to perform the test correctly, the patient must be awake enough. This will be assessed using the Richmond-Agitation-Sedation-Scale (RASS) first ranging from -5 (unarousable) to +4 (combative)
Time Frame
20 minutes after muscle relaxation
Secondary Outcome Measure Information:
Title
Incidence of mild agitation
Description
RASS +1, needing verbal command or short restraint < 1 minute
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Incidence of severe agitation
Description
RASS > 1, needing restraint > 1 minute or rescue medication)
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Use of rescue medication
Description
medication, dose, route
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Duration of seizure activity
Description
seconds
Time Frame
during procedure (estimated to be on average 10-15 minutes)
Title
Quality of seizure activity
Description
ideal, sufficient, insufficient
Time Frame
during procedure (estimated to be on average 10-15 minutes)
Title
Seizure Quality Index
Description
Seizure Quality Index (Kranaster et al., Eur Arch Psychiatry Clin Neurosci 2018) ranging from 0 to 5. Higher index indicates better response to treatment.
Time Frame
during procedure (estimated to be on average 10-15 minutes)
Title
Need for seizure terminating medication
Description
medication, dose, route
Time Frame
during procedure (estimated to be on average 10-15 minutes)
Title
Total number of electroconvulsive therapy sessions
Description
number
Time Frame
whole treatment course (12 ECT sessions, about 4 weeks)
Title
Reason for terminating or continuing the electroconvulsive series
Description
failure, response, remission, other reason
Time Frame
whole treatment course (12 ECT sessions, about 4 weeks)
Title
Length of post-anaesthesia care unit stay
Description
minutes
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Incidence of desaturation
Description
Oxygen saturation by pulse oximetry < 75%, irrespective of duration
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Incidence of hypotension
Description
any measurement with mean arterial pressure < 55 mmHg
Time Frame
during procedure (estimated to be on average 10-15 minutes)
Title
Incidence of bradycardia
Description
heart rate < 50 bpm for more than 1 minute
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Cardiovascular changes needing intervention
Description
number and type
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Use of cardiovascular medication
Description
medication, dose, route
Time Frame
post-anaesthesia care unit stay (up to 2 hours)
Title
Adverse events potentially attributable to ECT
Description
diagnosis
Time Frame
whole treatment course (12 ECT sessions, about 4 weeks)
Title
Adverse events potentially attributable to Study Drug
Description
diagnosis
Time Frame
whole treatment course (12 ECT sessions, about 4 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 and more; Scheduled for an elective series of ambulatory ECT sessions at the University Hospital Bern; Informed Consent as documented by signature (Appendix Informed Consent Form). Exclusion Criteria: Contraindications to the study drug, e. g. known allergy or hypersensitivity, hypotension, bradycardia, higher grade atrioventricular block; On regular Clonidine for another indication (e.g. arterial hypertension) Patients undergoing emergency ECT; Unable to consent (incapable of judgment, next-of-kin consent necessary or under tutelage); Inability to follow the procedures of the study, e. g. due to language barrier; Previous enrolment into the current study; Participation in another study with investigational drug within the 30 days preceding and during the present study; Enrolment of the investigator, his/her family members, employees and other dependent persons. Women who are pregnant or breast feeding; Intention to become pregnant during the course of the study; Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration (and 4 weeks thereafter), such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christian M Beilstein, MD
Phone
+41 31 632 24 82
Email
Christian.Beilstein@insel.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick Y Wüthrich, Prof, MD
Phone
+41 31 632 24 81
Email
Patrich.Wuethrich@insel.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Y Wüthrich, Prof, MD
Organizational Affiliation
Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Anaesthesiology and Pain Medicine, Bern University Hospital, University of Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian M Beilstein, MD
Phone
+41 31 632 24 83
Email
Christian.Beilstein@insel.ch
First Name & Middle Initial & Last Name & Degree
Patrick Y Wüthrich, Prof, MD
Phone
+41 31 632 24 83
Email
Patrick.Wuethrich@insel.ch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clonidine to Prevent Delirium After Electroconvulsive Therapy.

We'll reach out to this number within 24 hrs